scPharmaceuticals Provides Preliminary Unaudited Fourth Quarter and Full Year 2024 Financial Results

Core Insights - scPharmaceuticals Inc. expects preliminary unaudited fourth quarter 2024 net revenue to be approximately $12 million to$ 12.3 million, indicating a 99% growth over Q4 2023 at the mid-point of the range [1] - The company anticipates full year 2024 net revenue to be around $36.2 million to$ 36.5 million, compared to $13.6 million for full year 2023, representing a growth of 167% at the mid-point of the range [1][7] - The gross-to-net (GTN) discount for Q4 2024 is expected to be in the range of 18% to 19%, an increase from 15.7% in Q3 2024 [1][7] Financial Performance - Approximately 13,300 FUROSCIX doses were shipped in Q4 2024, reflecting a 23% increase from 10,800 doses shipped in Q3 2024 [7] - As of December 31, 2024, unaudited cash and cash equivalents were approximately$ 75.7 million, with an approximate 27% increase in accounts receivable over the balance as of September 30, 2024 [7] Strategic Initiatives - The growth in FUROSCIX net revenue is driven by ongoing expansion efforts, including collaborations with top Integrated Delivery Networks and hospital systems, as well as the initial impact of an expanded field sales force [2] - The company anticipates further growth in Class IV heart failure patients and plans to submit a supplemental New Drug Application (sNDA) for its Autoinjector product candidate mid-year, which is expected to accelerate future growth [2]